Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3280229 | 1.00 | — | — | |
| Water SCHEMBL9016951 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL22685 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL1226036 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL21825132 | 0.82 | — | — | |
| Water SCHEMBL3800293 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL5705172 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL5029036 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL10904055 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL11787694 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108834402-A | Method for generating tumor infiltrating T cell population | 莱特克斯生物制药股份有限公司 | 2018-11-16 | — | — | CN | disclosed |
| CN-102666541-B | Purine or deazapurine derivatives for the treatment of, in particular, viral infections | GILEAD SCIENCES, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-103619880-A | IP-10 Antibody Dose Escalation Method | BRISTOL MYERS SQUIBB CO | 2014-03-05 | — | — | CN | disclosed |
| CN-102834114-A | Fibronectin type III domain based multimeric scaffolds | MEDIMMUNE LLC | 2012-12-19 | — | — | CN | disclosed |
| EP-2205605-B1 | HYDRATED CRYSTALLINE ESTERS OF CAMPTOTHECIN FOR THE TREATMENT OF CANCER | CHRISTUS STEHLIN FOUNDATION FOR CANCER RES (US) | 2012-11-21 | — | — | EP | disclosed |
| CN-102666541-A | Purine or deazapurine derivatives for the treatment of, in particular, viral infections | GILEAD SCIENCES INC | 2012-09-12 | — | — | CN | disclosed |
| CN-101784696-B | Method for producing metal film, and use thereof | OMRON TATEISI ELECTRONICS CO | 2012-07-04 | — | — | CN | disclosed |
| CN-101528158-B | Bone model, bone filler and process for producing bone filler | NEXT21 KK | 2011-10-05 | — | — | CN | disclosed |
| US-20100324155-A1 | PREPARATION OF INORGANIC FOAM | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2205605-A1 | HYDRATED CRYSTALLINE ESTERS OF CAMPTOTHECIN FOR THE TREATMENT OF CANCER | The Christus Stehlin Foundation For Cancer Research (US) | 2010-07-14 | — | — | EP | disclosed |
| US-5288487-A | Treating myelodysplastic syndrome | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 1994-02-22 | — | — | US | disclosed |
| CN-1072686-A | Has Pyrmidine nucleoside derivatives of anti-tumor activity and its production and use | SANKYO CO (JP) | 1993-06-02 | — | — | CN | disclosed |
| EP-0257939-B1 | PLATINUM DERIVATIVES AND CANCER TREATMENTS | EFAMOL HOLDINGS PLC (GB) | 1991-04-24 | — | — | EP | disclosed |
| EP-0385385-A2 | Human monocyte-machrophage-CSF preparations | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
| US-4937262-A | FATTY AMINE-OR AMIDE-LINKED PLATINUM HALIDE; LIPOPHILIC RESIDUE AIDING IN METAL TRANSPORT ACROSS CELL MEMBRANE | EFAMOL LTD. (GB) | 1990-06-26 | — | — | US | disclosed |
| EP-0257939-A2 | Platinum derivatives and cancer treatments | EFAMOL HOLDINGS PLC (GB) | 1988-03-02 | — | — | EP | disclosed |
| US-4482569-A | ANTITUMOR AND -CARCINOGENIC AGENTS | NEDERLANDSE CENTRALE ORGANISATIE VOOR TOEGEPASTNATUURWETEN-SCHAPPELIJK ONDERZOEK (NL) | 1984-11-13 | — | — | US | disclosed |
| US-4466924-A | Platinum-diamine complexes, a process for the preparation thereof, a process for the preparation of a medicine using such a platinum-diamine complex for the treatment of malignant tumors in mice as well as a medicine thus formed | NEDERLANDSE CENTRALE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK (NL) | 1984-08-21 | — | — | US | disclosed |
| US-4431666-A | Platinum(IV)-diamine complexes, a process for the preparation thereof, a process for the preparation of a medicine using such a platinum(IV)-diamine complex for the treatment of malignant tumors in mice | NEDERLANDSE CENTRALE ORGANISATIE VOOR TOEGEPAST NATUURWELENSCHAPPELYK ONDERZOEK (NL) | 1984-02-14 | — | — | US | disclosed |
| US-4410544-A | Platinum-diamine complexes, a method for the preparation of a medicine using such a platinum-diamine complex for the treatment of malignant tumor in mice | Nederlandse Centrale Organisatie voor Toegespastnatuurwetenschappeliukond erzoek (NL) | 1983-10-18 | — | — | US | disclosed |